Immune cells from tumors could offer new hope for lung cancer patients
NCT ID NCT07498439
First seen Mar 31, 2026 · Last updated Jun 12, 2026 · Updated 14 times
Summary
This study tests whether using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), is safe for treating early-stage non-small cell lung cancer. About 50 adults with multiple lung nodules will receive TILs therapy. The main goal is to check for side effects and see how the immune cells behave.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY EARLY-STAGE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.